PA
VOR icon

Profund Advisors’s Vor Biopharma VOR Stock Holding History

Profund Advisors’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453K Buy
24,591
+2,576
+12% +$39K 0.01% 595
2026
Q1 		$393K Buy
+22,015
New +$310K 0.01% 631

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Profund Advisors's VOR Position: Q2 2026 in Review

Profund Advisors increased its Vor Biopharma (VOR) stake by 12% in Q2 2026, buying an estimated $39K and bringing the position to 24,591 shares worth $453K. The position accounts for 0.01% of the portfolio, ranked #595.

Profund Advisors first reported a position in VOR in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Profund Advisors held 24,591 shares of Vor Biopharma worth $453K as of Q2 2026.
  • Profund Advisors bought 2,576 Vor Biopharma shares in Q2 2026, an estimated $39K.
  • Vor Biopharma made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #595 holding.
  • Profund Advisors first reported a position in Vor Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.